Adaptive Biotechnologies Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Adaptive Biotechnologies Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 49% in 3 years; of every extra $100 of sales, $153 became extra profit. Higher than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-17.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 56% of Healthcare companies in United States.
Cash Locked Ratio
$19For every $100 of sales, $19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $25 tied up three years earlier.
Less money tied up than 60% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$153Sales grew 49% in 3 years; of every extra $100 of sales, $153 became extra profit.
Higher than 86% of Healthcare companies in United States.
Asset Productivity Ratio
+49% / -40%In 3 years sales changed by +49% while total assets changed by -40%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-5.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Lower than 60% of Healthcare companies in United States.
Tangible Assets Ratio
76%Of every $100 the company owns, $76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 55% of Healthcare companies in United States.
Tangible Net Worth Ratio
45%Of every $100 of net worth, $45 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 55% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Adaptive Biotechnologies Corporation made a loss over the last year. Adaptive Biotechnologies Corporation owes $0.76 for every $1 it owns. Adaptive Biotechnologies Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAdaptive Biotechnologies Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
27.26The share price is 27.26 times Adaptive Biotechnologies Corporation's book value per share, higher than 96% of Healthcare companies in United States.
Market cap
$3.9 BThe total market value of all of Adaptive Biotechnologies Corporation's shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$143 MWhat Adaptive Biotechnologies Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.90Net worth divided by the number of shares. The share price of $24.41 is 27.3 times this, which is the P/B above.
Return on equity (ROE)
-38.8%Adaptive Biotechnologies Corporation lost 38.8% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
Owes vs Owns
0.76×Adaptive Biotechnologies Corporation owes $0.76 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Dividend yield
NoneAdaptive Biotechnologies Corporation does not currently pay a dividend.
Revenue growth
+55%Revenue rose 55% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Profit growth
LossAdaptive Biotechnologies Corporation made a loss in each of the last two years.
Profit margin
-21.5%Adaptive Biotechnologies Corporation lost $21 for every $100 of revenue.
Interest cover
Not coveredAdaptive Biotechnologies Corporation's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAdaptive Biotechnologies Corporation held $148 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Adaptive Biotechnologies Corporation: $3.9 B ÷ $143 M (30 Jun 2026) = 27.3.
What is Adaptive Biotechnologies Corporation's return on equity?
Adaptive Biotechnologies Corporation lost 38.8% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
How much does Adaptive Biotechnologies Corporation owe compared with what it owns?
Adaptive Biotechnologies Corporation owes $0.76 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Does Adaptive Biotechnologies Corporation pay a dividend?
No. Adaptive Biotechnologies Corporation does not currently pay a dividend.
Is Adaptive Biotechnologies Corporation's revenue growing?
Revenue rose 55% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.